|
"okusaka t"的相關文件
顯示項目 11-19 / 19 (共2頁)
<< < 1 2
每頁顯示[10|25|50]項目
| 臺大學術典藏 |
2021-09-01T01:53:48Z |
Randomized phase iii study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: Gest study
|
Ueno H.; Ioka T.; Ikeda M.; Ohkawa S.; Yanagimoto H.; Boku N.; Fukutomi A.; Sugimori K.; Baba H.; Yamao K.; Shimamura T.; Sho M.; Kitano M.; ANN-LII CHENG; Mizumoto K.; Chen J.-S.; Furuse J.; Funakoshi A.; Hatori T.; Yamaguchi T.; Egawa S.; Sato A.; Ohashi Y.; Okusaka T.; Tanaka M. |
| 臺大學術典藏 |
2021-08-31T06:29:37Z |
Health-related quality of life in a randomised phase III study of gemcitabine plus S-1, S-1 alone and gemcitabine alone for locally advanced or metastatic pancreatic cancer: GEST study
|
Hagiwara Y.; Ohashi Y.; Okusaka T.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; ANN-LII CHENG; Kihara K.; Sato A.; Tanaka M. |
| 臺大學術典藏 |
2021-08-31T06:29:36Z |
Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer
|
Okusaka T.; Miyakawa H.; Fujii H.; Nakamori S.; Satoh T.; Hamamoto Y.; Ito T.; Maguchi H.; Matsumoto S.; Ueno H.; Ioka T.; Boku N.; Egawa S.; Hatori T.; Furuse J.; Mizumoto K.; Ohkawa S.; Yamaguchi T.; Yamao K.; Funakoshi A.; Chen J.S.; ANN-LII CHENG; Sato A.; Ohashi Y.; Tanaka M.; on behalf of the GEST group |
| 國家衛生研究院 |
2019-10 |
A phase III, randomized, double-blind, placebo-controlled, international study of durvalumab in combination with gemcitabine plus cisplatin for patients with advanced biliary tract cancers: TOPAZ-1
|
Oh, DY;Chen, LT;He, AR;Okusaka, T;Qin, S;Chin, S;Rokutanda, N;Uchinda, H;Vogel, A;Valle, JW;Kim, H |
| 國立成功大學 |
2019 |
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
|
Zhu, A.X.;Kang, Y.-K.;Yen, C.-J.;Finn, R.S.;Galle, P.R.;Llovet, J.M.;Assenat, E.;Brandi, G.;Pracht, M.;Lim, H.Y.;Rau, K.-M.;Motomura, K.;Ohno, I.;Merle, P.;Daniele, B.;Shin, D.B.;Gerken, Gerken G.;Borg, C.;Hiriart, J.-B.;Okusaka, T.;Morimoto, Morimoto M.;Hsu, Y.;Abada, P.B.;Kudo, M.;investigators, REACH-2 study |
| 國立成功大學 |
2018 |
Alpha-fetoprotein kinetics in patients with hepatocellular carcinoma receiving ramucirumab or placebo: An analysis of the phase 3 REACH study
|
Chau, I.;Park, J.O.;Ryoo, B.-Y.;Yen, C.-J.;Poon, R.;Pastorelli, D.;Blanc, J.-F.;Kudo, M.;Pfiffer, T.;Hatano, E.;Chung, H.C.;Kopeckova, Kopeckova K.;Phelip, J.-M.;Brandi, G.;Ohkawa, S.;Li, C.-P.;Okusaka, T.;Hsu, Y.;Abada, P.B.;Zhu, A.X. |
| 國家衛生研究院 |
2017-08 |
A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo
|
Ueno, M;Li, CP;Ikeda, M;Ishii, H;Mizuno, N;Yamaguchi, T;Ioka, T;Oh, DY;Ichikawa, W;Okusaka, T;Matsuyama, Y;Arai, D;Chen, LT;Park, YS;Furuse, J |
| 國立成功大學 |
2015-09 |
Ramucirumab (RAM) as a second-line treatment in patients with advanced hepatocellular carcinoma (HCC) following first-line therapy with sorafenib in the randomized phase III REACH study: Analysis of alpha-fetoprotein (AFP) kinetics during treatment
|
Chau, I.; Park, J. O.; Ryoo, B. Y.; Yen, C. J.; Poon, R.; Pastorelli, D.; Blanc, J. F.; Kudo, M.; Pfiffer, T. F.; Hatano, E.; Chung, H. C.; Kubackova, K.; Phelip, J. M.; Brandi, G.; Ohkawa, S.; Li, C. P.; Okusaka, T.; Yang, L.; Abada, P.; Zhu, A. |
| 國立成功大學 |
2014-11 |
Results of a phase I, open-label, multicentre study to assess the safety, tolerability, pharmacokinetics and preliminary antitumour activity of AZD9150 in patients with advanced/metastatic hepatocellular carcinoma
|
Kang, Y. K.; Ryoo, BY; Kim, TY; Lee, KH; Lim, HY; Lee, SJ; Ikeda, M; Okusaka, T; Nadano, S; Lin, CC; Poon, TP; Yen, CJ; McCoon, P; Neumann, F; Vishwantahan, K; DuPont; Lyne, P |
顯示項目 11-19 / 19 (共2頁)
<< < 1 2
每頁顯示[10|25|50]項目
|
